<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051464</url>
  </required_header>
  <id_info>
    <org_study_id>16-301</org_study_id>
    <nct_id>NCT03051464</nct_id>
  </id_info>
  <brief_title>No Surgery Trial / Two Dose-escalation Strategies</brief_title>
  <acronym>Morpheus</acronym>
  <official_title>A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study of 145 patients. Patients with a clinical T2-3 N0 rectal cancer will be&#xD;
      randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or&#xD;
      Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard&#xD;
      chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a&#xD;
      brachytherapy boost of 30 Gy in 3 fractions).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is becoming clear that there is a now an international consensus that rectal cancer&#xD;
      research efforts need to be more focused in optimizing a non-surgical approach. This concept&#xD;
      is very relevant to an ageing patient population with multiple co-morbidities regularly seen&#xD;
      at the Jewish General Hospital and across the province. After interim analysis on 40 patients&#xD;
      of the pilot study a phase III study is proposed. We are therefore proposing a phase III&#xD;
      multicentric study of 145 patients to compare the two best known radiation dose escalation&#xD;
      strategies and to achieve a complete clinical response. Patients with a clinical T2-3 N0-1&#xD;
      rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25&#xD;
      with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to&#xD;
      arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and&#xD;
      followed by a brachytherapy boost of 30 Gy in 3 fractions). Patients that have a high risk of&#xD;
      recurrence or with more advanced stages of the disease will be excluded from the study, as&#xD;
      only the local disease is being treated. The primary outcome for this proposal is rectum&#xD;
      preservation in treated patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2017</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectum preservation in treated patients</measure>
    <time_frame>2 years post treatment</time_frame>
    <description>Number of participants that are complete clinical responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Recurrence</measure>
    <time_frame>2 years post treatment</time_frame>
    <description>Number of participants with Local recurrence as assessed by tests during follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years post treatment</time_frame>
    <description>The time between the date of randomization and recurrence, either in the pelvis or metastases. Patients without an event will be censored at the last date the patient was known to be disease-free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years post treatment</time_frame>
    <description>The time between date of randomization and date of death due to any causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of life</measure>
    <time_frame>5 years post treatment</time_frame>
    <description>Quality of life Questionnaires over different time point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Stage II Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiation + EBRT Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiation + HDRBT Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Complete responders and Non-complete responders</intervention_name>
    <description>Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.</description>
    <arm_group_label>Chemoradiation + EBRT Boost</arm_group_label>
    <arm_group_label>Chemoradiation + HDRBT Boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiation + EBRT Boost</intervention_name>
    <description>45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5</description>
    <arm_group_label>Chemoradiation + EBRT Boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiation + HDRBT Boost</intervention_name>
    <description>45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions</description>
    <arm_group_label>Chemoradiation + HDRBT Boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rectal cancer patients, clinically staged as T2-T3 by MRI or endoscopic/trans-rectal&#xD;
             ultrasound&#xD;
&#xD;
          -  Rectal cancer staged as N0 by MRI or EUS/TRUS&#xD;
&#xD;
          -  No metastatic lesion&#xD;
&#xD;
          -  Rectal tumor occupying less than half of the circumference&#xD;
&#xD;
          -  Tumor less than 5 cm on its largest dimension&#xD;
&#xD;
          -  Tumor located at less than 10 cm from the anal verge&#xD;
&#xD;
          -  Tumor penetration less than 5 mm in the mesorectal fat&#xD;
&#xD;
          -  Tumor accessible for brachytherapy&#xD;
&#xD;
          -  Lumen accessible for colonoscopy&#xD;
&#xD;
          -  Patient should be a suitable candidate for brachytherapy and chemotherapy&#xD;
&#xD;
          -  Older than 18 years of age&#xD;
&#xD;
          -  Adequate birth control measures in women of childbearing potential&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with previous pelvic radiation&#xD;
&#xD;
          -  Evidence of distant metastasis&#xD;
&#xD;
          -  Extension of malignant disease to the anal canal&#xD;
&#xD;
          -  Tumors staged as T4&#xD;
&#xD;
          -  Tumors larger than 5 cm in length&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Te Vuong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Mortimer Jewish General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alix Legrand, BA</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>28443</phone_ext>
    <email>alix.legrand.ccomtl@ssss.gouv.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alix Legrand, BA</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>28443</phone_ext>
      <email>alix.legrand.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Te Vuong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Te Vuong</investigator_full_name>
    <investigator_title>Director, Radiation Oncology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

